2op3: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2op3.png|left|200px]] | [[Image:2op3.png|left|200px]] | ||
{{STRUCTURE_2op3| PDB=2op3 | SCENE= }} | {{STRUCTURE_2op3| PDB=2op3 | SCENE= }} | ||
===The structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substrate Activity Screening (SAS) method=== | ===The structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substrate Activity Screening (SAS) method=== | ||
{{ABSTRACT_PUBMED_17469812}} | {{ABSTRACT_PUBMED_17469812}} | ||
==About this Structure== | ==About this Structure== | ||
[[2op3]] is a 2 chain structure of [[Cathepsin]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2OP3 OCA]. | |||
==See Also== | |||
*[[Cathepsin|Cathepsin]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:017469812</ref><references group="xtra"/> | ||
[[Category: Cathepsin S]] | [[Category: Cathepsin S]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| Line 33: | Line 24: | ||
[[Category: Tsuruoka, H.]] | [[Category: Tsuruoka, H.]] | ||
[[Category: Cathepsin s]] | [[Category: Cathepsin s]] | ||
[[Category: Hydrolase]] | |||
[[Category: Nonpeptidic]] | [[Category: Nonpeptidic]] | ||
[[Category: Substrate activity screening]] | [[Category: Substrate activity screening]] | ||
Revision as of 05:27, 27 July 2012
The structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substrate Activity Screening (SAS) methodThe structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substrate Activity Screening (SAS) method
Template:ABSTRACT PUBMED 17469812
About this StructureAbout this Structure
2op3 is a 2 chain structure of Cathepsin with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Inagaki H, Tsuruoka H, Hornsby M, Lesley SA, Spraggon G, Ellman JA. Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. J Med Chem. 2007 May 31;50(11):2693-9. Epub 2007 May 1. PMID:17469812 doi:http://dx.doi.org/10.1021/jm070111+